<DOC>
	<DOC>NCT00159627</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of KW-3902IV compared to placebo and to determine the diuretic effect of KW-3902IV compared to placebo in patients hospitalized with volume overload due to CHF who are refractory to high dose diuretic therapy.</brief_summary>
	<brief_title>Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Rolofylline</mesh_term>
	<criteria>History of CHF for greater than 3 months, Receiving oral/IV diuretic therapy Hospitalized for therapy for HF and edema that has not responded to diuretic therapy. Signs and symptoms of ongoing volume overload Myocardial infarction in past 14 days Clinical evidence of acute coronary syndrome causing worsening of HF, Pregnant or breastfeeding, Severe, uncorrected primary valvular disease, constrictive pericarditis, restrictive or hypertrophic cardiomyopathy, Automated implanted cardiac defibrillator (AICD) or synchronization device implanted within the preceding 7 days, Require mechanical ventilation, ultrafiltration, or hemodialysis at the time of enrollment, Deterioration due to an acute or superimposed condition requiring therapy other than diuretics Symptomatic ventricular tachycardia, Severe concomitant primary hepatic disease, Severe pulmonary disease, Any other concomitant lifethreatening disease, CVA in the preceding 6 months, Hypotension, Participated in another clinical trial within 30 days, Acute contrast nephropathy, Admitted for heart transplant surgery or have had a heart transplant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>heart failure, congestive</keyword>
	<keyword>diuretic</keyword>
</DOC>